• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Betterlife Pharma Inc (OP:BETRF)

    0.0400 +0.0083 (+26.18%)
    Streaming Delayed Price Updated: 11:57 AM EST, Jan 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Betterlife Pharma Inc

    News headline image
    Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More ↗
     
    Via Benzinga
    News headline image
    Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review ↗
     
    Via Benzinga
    News headline image
    Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More ↗
    World's Largest Psychedelics Conference Boasts 12K Attendees 
    Via Benzinga
    News headline image
    BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives ↗
    Psychedelics biotech BetterLife Pharma Inc. (OTCQB: BETRF) is fast-tracking its U.S. 
    Via Benzinga
    News headline image
    Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More ↗
    Science Conference In Dubai, UAE Hosts Discussion On Psychedelics Research 
    Via Benzinga
    News headline image
    BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue ↗
    Psychedelics biotech BetterLife Pharma (OTCQB: BETRF) announced its non-hallucinogenic LSD derivative, BETR-001, is progressing through IND-enabling studies  toward expected clinical studies targeting... 
    Via Benzinga
    News headline image
    Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More ↗
    Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
    Via Benzinga
    News headline image
    Mood Disorders Could Get An Alternative Treatment With This Next-Gen, Non-Hallucinogenic Psychedelic ↗
    The next-generation psychedelics R&D business is up and running, as BetterLife Pharma Inc. 
    Via Benzinga
    News headline image
    BetterLife Engages Canadian Healthcare Investment Firm, Aims For Clinical Trial Programs ↗
    BetterLife Pharma (OTCQB: BETRF), a non-hallucinogenic psychedelics biotech company, has contracted Bloom Burton Securities Inc. for strategic advisory services. 
    Via Benzinga
    News headline image
    Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives ↗
    In parallel with working towards discovering and advancing therapeutic psychedelics, biopharma companies are continuously protecting their findings. 
    Via Benzinga
    News headline image
    Study Reveals BetterLife's LSD Analogue Boosts Structural Neuroplasticity Without Hallucinogenic Side Effects ↗
    A recent paper has provided new evidence that LSD has outstanding nootropic effects, believed to originate in the drug’s neuroplasticity promotion, in both animals and humans. 
    Via Benzinga
    News headline image
    BetterLife's Preclinical Studies Of BETR-001 For Depression Gets Additional Sponsorship By Mitacs ↗
    Biotech psychedelics company BetterLife Pharma Inc. (OTCQB: BETRF) in collaboration with the Carleton University Dept. 
    Via Benzinga
    News headline image
    EXCLUSIVE: Can Non-Hallucinogenic Psychedelic Compounds Treat Mental Health Conditions? This Company Thinks So! ↗
    Image Provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
    Via Benzinga
    News headline image
    Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗
    The Week In Psychedelics 
    Via Benzinga
    News headline image
    What Do You Really Know About Psychedelics And Psychedelics Stocks? ↗
    According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use. That... 
    Via Benzinga
    News headline image
    There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗
    Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.